Cardiac sympathetic denervation for refractory ventricular arrhythmias

Refractory ventricular tachycardia (VT), ventricular fibrillation (VF), and electrical storm can continue even after antiarrhythmic drugs, catheter ablation, and implantable cardioverter-defibrillator (ICD) therapy. In carefully selected patients, cardiac sympathetic denervation (CSD) offers a surgical way to reduce adrenergic drive when recurrent ventricular arrhythmias remain life-threatening.

The procedure is used in inherited arrhythmia syndromes and structural heart disease, although the evidence base is still developing. Outcomes are shaped by the underlying diagnosis, ventricular function, completeness of denervation, previous ablation, and the expertise of the multidisciplinary team. Current arrhythmia research helps clinicians place surgical results within the wider electrophysiology literature.

Why sympathetic denervation is considered

The sympathetic nervous system can increase myocardial excitability, shorten or disperse repolarisation, and lower the threshold for ventricular arrhythmia. This effect is particularly important during fever, emotional stress, exercise, hypokalaemia, heart failure, or repeated ICD shocks. By interrupting selected thoracic sympathetic pathways, CSD aims to reduce the adrenergic triggers that sustain VT or VF.

Most operations involve removal of part of the lower cervical and upper thoracic sympathetic chain, commonly including the stellate ganglion and thoracic ganglia. A left-sided procedure is often the initial strategy, while bilateral CSD may be considered for persistent events, severe disease, or selected genetic syndromes. The decision should be made jointly by electrophysiologists, cardiothoracic surgeons, anaesthetists, genetic specialists, and intensive care clinicians.

Patients most likely to benefit

The strongest clinical rationale is often found in catecholaminergic polymorphic ventricular tachycardia (CPVT) and long-QT syndrome when beta-blockers, flecainide where appropriate, lifestyle measures, and ICD management have not controlled events. CSD may also be considered in patients with recurrent polymorphic VT or VF who cannot tolerate medication or who have frequent shocks despite optimised care.

In ischaemic or non-ischaemic cardiomyopathy, surgery is generally reserved for highly selected cases. Recurrent monomorphic VT should prompt assessment for myocardial ischaemia, scar-related re-entry, ventricular aneurysm, medication toxicity, and the feasibility of repeat catheter ablation before CSD is offered. In Australia, referral often moves from a regional hospital to a tertiary electrophysiology service in Sydney, Melbourne, Brisbane, Perth, or Adelaide, especially when an electrical storm requires surgical and intensive-care support.

How surgical outcomes are measured

Studies commonly report freedom from sustained VT or VF, reduction in ICD therapies, survival, transplant-free survival, and perioperative complications. A meaningful outcome may be a substantial fall in shock burden rather than complete elimination of arrhythmia. Patients can still experience isolated ectopy, non-sustained VT, or a later recurrence as ventricular disease progresses.

Published series generally suggest that CSD can reduce ventricular arrhythmia episodes and ICD shocks in selected patients, but most evidence comes from retrospective cohorts, single-centre experiences, and relatively small populations. Results are therefore difficult to compare directly. Genetic syndromes, where sympathetic activation is a central mechanism, may show a more consistent response than advanced scar-mediated cardiomyopathy with severe left ventricular dysfunction.

The role of the procedure alongside ablation

CSD is not usually a substitute for catheter ablation, ICD protection, or disease-specific medication. It is better understood as part of a layered treatment strategy. Before surgery, clinicians should correct electrolytes, treat heart failure, review QT-prolonging medicines, manage ischaemia, and assess whether ablation can remove a dominant arrhythmogenic substrate.

The sequence varies according to urgency. In an unstable electrical storm, temporary sedation, general anaesthesia, autonomic modulation, mechanical circulatory support, or urgent ablation may be required before a definitive operation. For patients with recurrent events over months, CSD can be planned after an MDT review that considers imaging, device electrograms, programmed stimulation, genetic findings, and the patient’s goals.

Techniques and perioperative considerations

Video-assisted thoracoscopic surgery and robotic approaches can reduce the incision burden compared with open thoracotomy, although the optimal technique depends on local expertise and patient anatomy. The surgeon must identify the intended sympathetic chain accurately while protecting the phrenic nerve, vagus nerve, intercostal structures, and pleura. Bilateral surgery may be performed during one anaesthetic or in staged procedures.

Potential complications include pneumothorax, bleeding, pleural effusion, infection, neuropathic pain, altered sweating, and transient or persistent Horner syndrome. Changes in heart rate or blood pressure may also occur, particularly in patients with advanced cardiac disease. Postoperative monitoring should include rhythm surveillance, device interrogation, respiratory assessment, pain control, and a plan for restarting or adjusting antiarrhythmic therapy.

Australian hospitals must also account for practical access issues. A patient from the Northern Territory or regional Western Australia may need prolonged travel, accommodation for family, and coordinated follow-up after discharge. Public hospital pathways may involve waiting lists and transfer agreements, while private care can offer faster scheduling but exposes patients to substantial out-of-pocket expenses and insurer-specific coverage rules.

Interpreting recurrence and long-term follow-up

Recurrence after CSD does not automatically mean that the operation failed. It may reflect incomplete denervation, reinnervation, progression of cardiomyopathy, a new scar-related circuit, medication non-adherence, or a trigger such as infection or electrolyte disturbance. Device-recorded episodes should be reviewed carefully because inappropriate shocks, atrial arrhythmias, and oversensing can be mistaken for recurrent VT or VF.

Long-term management includes ICD programming, beta-blockade when tolerated, heart failure treatment, exercise and medication counselling, and psychological support after repeated shocks. Patients with CPVT or long-QT syndrome still require family screening and genetic counselling. For Australians, follow-up may involve a shared-care arrangement between a tertiary centre and a local cardiologist, with telehealth helping reduce repeated journeys from rural and remote communities.

Building a stronger evidence base

Future studies should define patient selection more precisely and report outcomes separately for CPVT, long-QT syndrome, ischaemic cardiomyopathy, and non-ischaemic cardiomyopathy. Standardised descriptions of surgical levels, unilateral versus bilateral procedures, preoperative ablation, medication use, ICD programming, and follow-up duration would make results easier to interpret.

Prospective registries could also capture quality of life, hospital admissions, health-care costs, neurological symptoms, and the effect of CSD on return to work or normal activities. These outcomes matter in Australia’s mixed public and private health system, where treatment value includes travel, rehabilitation, family disruption, and repeated emergency presentations. Researchers preparing a surgical outcomes study can review the author guidelines before submitting work for peer review.

What the evidence means for clinical practice

For an individual with refractory ventricular arrhythmias, CSD should be discussed early enough to avoid a cycle of repeated shocks and deteriorating health, but not so early that reversible triggers and effective ablation options are overlooked. A clear review of the arrhythmia mechanism, ventricular function, inherited disease status, and previous treatment response is essential.

The current evidence supports CSD as a valuable adjunct for selected high-risk patients rather than a universal solution. Its greatest benefit may be a durable reduction in arrhythmia burden, fewer ICD shocks, and a safer opportunity to stabilise the patient while longer-term therapies continue. Decisions should be documented through an experienced MDT and aligned with the patient’s preferences, procedural risk, access to follow-up, and realistic expectations.

Clinicians and researchers can use the Journal of Arrhythmia’s open-access resources to follow emerging evidence on autonomic modulation, ventricular arrhythmia surgery, ablation, and device therapy. Careful reporting of outcomes from Australian and international centres will help refine selection, improve counselling, and establish where cardiac sympathetic denervation provides the greatest clinical value.